Drug intelligence / Profile preview

DB-029.01

Development stage: Discontinued
Lead developer: Digna Biotech
Modality: Peptides, Small Molecules

Overview

DB-029.01 is a therapeutic candidate developed by Digna Biotech for the treatment of pulmonary fibrosis. It functions as an inhibitor of the transforming growth factor beta receptor 2 (TGFBR2). The TGF-β signaling pathway is a central driver of fibrotic processes, including the activation of fibroblasts and the excessive production of extracellular matrix components like collagen. By targeting TGFBR2, DB-029.01 aims to interrupt this signaling cascade to halt or reverse the progression of lung scarring. Development of the compound was discontinued following the dissolution of Digna Biotech.

Targets

TGFBR2 (TGF-β receptor type 2)

Beyond the preview

Go deeper on DB-029.01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on DB-029.01.

Explore the full profile